-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Protagenic Therapeutics (OTCMKTS:PTIX) Stock Price Passes Below 200-Day Moving Average of $0.80
Protagenic Therapeutics (OTCMKTS:PTIX) Stock Price Passes Below 200-Day Moving Average of $0.80
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.80 and traded as low as $0.62. Protagenic Therapeutics shares last traded at $0.65, with a volume of 61,694 shares traded.
Protagenic Therapeutics Stock Performance
The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.47 and a quick ratio of 19.47.
Get Protagenic Therapeutics alerts:Institutional Investors Weigh In On Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned about 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. 11.09% of the stock is currently owned by institutional investors and hedge funds.
About Protagenic Therapeutics
(Get Rating)Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Featured Articles
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.80 and traded as low as $0.62. Protagenic Therapeutics shares last traded at $0.65, with a volume of 61,694 shares traded.
在周一的交易中，普罗吉治疗公司(OTCMKTS：PTIX-GET Rating)的股价跌破了200日移动均线。该股的200日移动均线为0.80美元，最低交易价格为0.62美元。普罗吉治疗公司的股票最新报0.65美元，总成交量为61,694股。
Protagenic Therapeutics Stock Performance
普罗地亚治疗类股业绩
The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.47 and a quick ratio of 19.47.
该股的50日简单移动均线为0.68美元，200日简单移动均线为0.80美元。该公司的债务权益比为0.04，流动比率为19.47，速动比率为19.47。
Institutional Investors Weigh In On Protagenic Therapeutics
机构投资者对普罗替尼治疗公司的看法
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned about 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. 11.09% of the stock is currently owned by institutional investors and hedge funds.
一家机构投资者最近提高了其在普罗吉治疗公司股票的头寸。复兴科技有限责任公司最近提交给美国证券交易委员会的文件显示，该公司第一季度将其在普罗吉治疗公司(OTCMKTS：PTIX-GET Rating)的持股比例提高了69.2%。在此期间，该公司额外收购了41,800股生物技术公司的股票，目前持有102,200股。在最近一次报告所述期间结束时，复兴技术有限责任公司拥有普罗吉治疗公司约0.59%的股份，价值8.3万美元。该公司11.09%的股票目前由机构投资者和对冲基金持有。
About Protagenic Therapeutics
关于前列腺素治疗学
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
前列基因治疗公司是一家生物制药公司，致力于发现和开发治疗与压力相关的神经精神和情绪障碍的疗法。它的先导化合物是PT00114，这是Teneurin羧基末端相关肽的合成形式，Teneurin羧基末端相关肽是一种内源性大脑信号肽，可以抑制过度活跃的应激反应。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
- 免费获取StockNews.com关于前列腺素治疗(PTIX)的研究报告
- MarketBeat播客：股票投资组合中的梦幻足球策略
- 你应该在怪物需求之前买入这些铜库存吗？
- 三只能够渡过风暴般的衰退的工业股票
- 床上洗澡和肉食之外：Bynd是下一个大空头吗？
- Denbury因出售传言而上涨，但落后于其他能源公司
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普罗汀治疗日报》的新闻和评级-在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯，收到对Protag Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧